Thermo Fisher Scientific (TMO) Getting Favorable Press Coverage, Study Finds
News articles about Thermo Fisher Scientific (NYSE:TMO) have been trending positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than 6,000 blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Thermo Fisher Scientific earned a media sentiment score of 2.55 on their scale. InfoTrie also gave media coverage about the medical research company an news buzz score of 7 out of 10, meaning that recent news coverage is likely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have effected Thermo Fisher Scientific’s score:
- Analysts Anticipate Thermo Fisher Scientific Inc. (TMO) Will Announce Quarterly Sales of $6.24 Billion (americanbankingnews.com)
- Becton, Dickinson Closes Out Its Fiscal Year With a Bang (finance.yahoo.com)
- $3.19 EPS Expected for Thermo Fisher Scientific Inc. (TMO) This Quarter (americanbankingnews.com)
- Thermo Fisher Scientific (TMO) Earns News Impact Rating of 2.08 (americanbankingnews.com)
- Global Biological Safety Cabinet Market 2018 – ESCO, Thermo Fisher Scientific Inc, AIRTECH, Telstar Life-Sciences … (techgazette24.com)
A number of brokerages recently weighed in on TMO. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $259.00 price target on the stock in a research note on Monday, July 30th. Leerink Swann lifted their price target on Thermo Fisher Scientific from $239.00 to $255.00 and gave the stock an “outperform” rating in a research note on Thursday, July 26th. Cleveland Research cut Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research note on Thursday, October 18th. Morgan Stanley lifted their target price on Thermo Fisher Scientific from $254.00 to $260.00 and gave the company an “overweight” rating in a research note on Thursday, October 25th. Finally, Robert W. Baird lifted their target price on Thermo Fisher Scientific from $256.00 to $264.00 and gave the company an “outperform” rating in a research note on Thursday, October 25th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $261.45.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 24th. The medical research company reported $2.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.55 by $0.07. Thermo Fisher Scientific had a return on equity of 16.49% and a net margin of 10.75%. The company had revenue of $5.92 billion for the quarter, compared to analysts’ expectations of $5.70 billion. During the same quarter in the previous year, the business posted $2.31 EPS. The business’s revenue for the quarter was up 15.7% on a year-over-year basis. On average, equities research analysts anticipate that Thermo Fisher Scientific will post 11.04 earnings per share for the current year.
Thermo Fisher Scientific announced that its Board of Directors has initiated a stock buyback plan on Friday, September 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 2.1% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, January 15th. Shareholders of record on Monday, December 17th will be paid a dividend of $0.17 per share. The ex-dividend date is Friday, December 14th. This represents a $0.68 annualized dividend and a yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 7.17%.
In other news, CEO Marc N. Casper sold 125,520 shares of Thermo Fisher Scientific stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $247.50, for a total transaction of $31,066,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.49% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: “Thermo Fisher Scientific (TMO) Getting Favorable Press Coverage, Study Finds” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2018/11/13/thermo-fisher-scientific-tmo-getting-favorable-press-coverage-study-finds.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: How do investors use RSI to grade stocks?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.